Immunogenicity of COVID ‐19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy
Summary: Immune responses to primary COVID‐19 vaccination were investigated in 58 patients with follicular lymphoma (FL) as part of the PETReA trial of frontline therapy (EudraCT 2016–004010‐10). COVID‐19 vaccines (BNT162b2 or ChAdOx1) were administered before, during or after cytoreductive treatmen...
Hauptverfasser: | Lim, YJ, Ward, V, Brown, A, Phillips, E, Kronsteiner, B, Malone, T, Jennings, D, Healy, S, Longet, S, James, T, Thomson, P, Farrell, L, Oates, M, Jackson, R, Morrison, A, Burns, M, Carroll, M, Klenerman, P, Turtle, L, Naisbitt, D, Rhodes, M, Robinson, K, Gatto, S, Young, M, Eyre, TA, Eyre, DW, Dunachie, S, Barnes, E |
---|---|
Format: | Journal article |
Sprache: | English |
Veröffentlicht: |
Wiley
2024
|
Ähnliche Einträge
Ähnliche Einträge
-
P1095: COVID-19 VACCINE RESPONSES IN FOLLICULAR LYMPHOMA: DETERMINANTS OF HUMORAL AND CELLULAR IMMUNITY IN THE PETREA TRIAL OF FRONTLINE CHEMOIMMUNOTHERAPY
von: Yeong Jer Lim, et al.
Veröffentlicht: (2023-08-01) -
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma
von: Reid W. Merryman, et al.
Veröffentlicht: (2023-02-01) -
Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of Chemoimmunotherapy
von: María Elena Cabrera, et al.
Veröffentlicht: (2024-09-01) -
Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy
von: Hiu Lam Agnes Yuen, et al.
Veröffentlicht: (2020-08-01) -
Symptomatic Follicular Lymphoma: Complete Remission After Chemoimmunotherapy with Bendamustine–Rituximab
von: Wulyo Rajabto, et al.
Veröffentlicht: (2024-04-01)